The pair plan to supply licensed compounders if the FDA adds the peptides to its bulk substance list. GLP-1 drugs are left out of the deal.
Recap by typeshit. Full story at AOL.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Miller credits a 25% drop in weight with yearly savings in healthcare spending per person and brings up retatrutide's results.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
Loading…